Pharus Diagnostics key facts
as of Oct 2026- Developer and provider of liquid biopsy tests intended for the early detection of cancer.
- Pharus Diagnostics is valued at approximately $43.0M as of Oct 2026 (last reported valuation).
- It has raised $17.1M; the latest was Early Stage VC ($6.1M) in Apr 2025.
- Notable investors include Lee Family Office, CK Hutchison, CK Life Sciences International, Larta Institute, QuarkBio.
- Status: Privately Held (backing).
Pharus Diagnostics's last reported valuation, Apr 2025. Nothing priced has surfaced since.
- ·Watch Pharus Diagnostics: the Monday email on marks, rounds and moves
Pharus Diagnostics funding rounds
No funding rounds for Pharus Diagnostics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Pharus Diagnostics
5Pharus Diagnostics valuation
Pharus Diagnostics's last reported valuation was $43 million in Apr 2025. No priced round, secondary trade or fund mark has surfaced since.
Pharus Diagnostics investors
5 investors are on record for Pharus Diagnostics, including Lee Family Office, CK Hutchison, CK Life Sciences International and Larta Institute.
About Pharus Diagnostics
Developer and provider of liquid biopsy tests intended for the early detection of cancer. The company's tests leverage its enhanced RNA-based genetic testing solution and integrates additional diverse omics data to achieve cancer detection in a single analysis, enabling users to manage their health outcomes better and earlier.
- Sector
- Healthcare
- HQ
- Zhubei City, Taiwan
- Founded
- 2022
- Employees
- 21
- Website
- pharusdx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.